Proposed a model for understanding which patients
 benefit from immunotherapy

Immunotherapy is revolutionizing cancer treatment however many patients do not benefit. Our group has proposed a model for understanding which patients will benefit from immunotherapy known as the “T cell- inflamed tumor microenvironment.” Our group has also recently defined the first cancer-specific molecular change (WNT/β-catenin) that leads to exclusion of immune cells from melanoma. In this research, we will analyze 30 solid tumor cancers by gene expression and exonic DNA sequencing from The Cancer Genome Atlas, looking for molecular pathways associated with immune exclusion in each tumor type. After validating our findings in human cancer specimens we will propose a rationally developed clinical trial of a targeted molecular inhibitor with immunotherapy.